# Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

> **NCT01192165** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 169 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Trametinib (GSK1120212)
- **DRUG:** Docetaxel
- **DRUG:** Erlotinib
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** nab-Paclitaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01192165
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-14
- **Primary completion:** 2013-10-07
- **Final completion:** 2013-10-07
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01192165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01192165, "Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01192165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*